A new report, now available on ASDReports, predicts the world market for next-generation biologics will grow by more than 50% in 2014. That follows 45% growth in the market in 2013. Double-digit growth is forecast for that worldwide market up to 2024. Those predictions and others appear in Next-Generation Biologics: R&D, Industry and Market 2014-2024.
The new study finds regenerative medicine - including stem cell therapies, gene therapies and tissue-engineered products - accounted for the largest share of the next-generation biologics market in 2013, with revenues close to $1bn in that year. The launch of new stem cell therapies and gene therapies from 2014 will drive growth in the regenerative medicine submarket to 2024. However, in that year, it will only be the second largest segment of the next-generation biologics market. The new report forecasts faster growth for the next-generation antibody and insulin therapy sectors, driven by the launch of pipeline therapies, as well as rising incidence of cancer and diabetes.
Richard Lang, a pharmaceutical industry analyst, said: “Biological therapies have grown to hold a significant position in the treatment of many chronic and serious diseases, including cancer, diabetes and autoimmune diseases. Biologics now account for seven of the 10 bestselling prescription pharmaceuticals, in terms of revenue. This will rise to eight by the end of 2014.
“Next-generation biologics will address shortcomings in the current generation of therapies, including inconvenient dosing and administration, and concerns over side effects. Common developmental trends we identified include sustained release therapies for less frequent dosing and reformulations for oral and topical administration.
“Next-generation biologics that treat new indications will be launched in the coming 10 years. Regenerative medicine offers a novel approach to treating serious acute and chronic diseases, with many late-stage developers targeting cardiovascular disease. Four gene therapies for cardiovascular disease could be launched by 2018. Next-generation antibody fragments and antibody-like proteins offer benefits over current antibody treatments - such as size, multivalency and stability - that allow targeting in new indications and via routes other than injection.”
The new report's data forecasts the world market for next-generation biologics, as well as providing forecasts and other analyses for six leading market sectors, as well as 11 subsectors: